These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 28039098)

  • 1. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
    Fernández I; Muñoz-Gómez R; Pascasio JM; Baliellas C; Polanco N; Esforzado N; Arias A; Prieto M; Castells L; Cuervas-Mons V; Hernández O; Crespo J; Calleja JL; Forns X; Londoño MC
    J Hepatol; 2017 Apr; 66(4):718-723. PubMed ID: 28039098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
    Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
    Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR.
    Michels FBL; Amaral ACC; Carvalho-Filho RJ; Vieira GA; Souza ALDS; Ferraz MLG
    Arq Gastroenterol; 2020; 57(1):45-49. PubMed ID: 32294735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.
    Saxena V; Khungar V; Verna EC; Levitsky J; Brown RS; Hassan MA; Sulkowski MS; O'Leary JG; Koraishy F; Galati JS; Kuo AA; Vainorius M; Akushevich L; Nelson DR; Fried MW; Terrault N; Reddy KR
    Hepatology; 2017 Oct; 66(4):1090-1101. PubMed ID: 28504842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
    Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
    PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Real-life' experience with direct-acting antiviral agents for HCV after kidney transplant.
    Fabrizi F; Alonso C; Palazzo A; Anders M; Reggiardo MV; Cheinquer H; Zuain MGV; Figueroa S; Mendizabal M; Silva M; Ridruejo E;
    Ann Hepatol; 2021; 25():100337. PubMed ID: 33684523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
    Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P
    Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals.
    Liu CH; Lee MH; Lin JW; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Hepatol; 2020 May; 72(5):839-846. PubMed ID: 31790766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.
    Xue Y; Zhang LX; Wang L; Li T; Qu YD; Liu F
    World J Gastroenterol; 2017 Aug; 23(32):5969-5976. PubMed ID: 28932089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients.
    Huang H; Tang H; Deng H; Shen J; Zhou Q; Xie W; Wu J; Chen J
    Transpl Infect Dis; 2019 Feb; 21(1):e13018. PubMed ID: 30369001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients With Directly Acting Antiviral Agents.
    Lubetzky M; Chun S; Joelson A; Coco M; Kamal L; Ajaimy M; Gaglio P; Akalin E; De Boccardo G
    Transplantation; 2017 Jul; 101(7):1704-1710. PubMed ID: 28009781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
    Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
    Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
    Mansour M; Hill L; Kerr J
    Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients.
    Eisenberger U; Guberina H; Willuweit K; Bienholz A; Kribben A; Gerken G; Witzke O; Herzer K
    Transplantation; 2017 May; 101(5):980-986. PubMed ID: 27495770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
    Hanif FM; Mandhwani R; Lail G; Luck NH; Aziz T
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):198-201. PubMed ID: 30777554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Novel antiviral agents for the treatment of HCV among renal transplant recipients].
    Fabrizi F; Donato FM; Messa P
    G Ital Nefrol; 2017 Aug; 34(4):35-50. PubMed ID: 28762681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
    J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
    Beig J; Orr D; Harrison B; Gane E
    Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of antiviral treatment in hepatitis C virus liver transplant patients off immunosuppression in the direct acting antivirals era: A case series.
    Campos-Varela I; Agudelo EZ; Terrault NA
    Clin Transplant; 2018 Jul; 32(7):e13303. PubMed ID: 29851150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.